Effect of Combination Treatment of Rapamycin and Isoflavones on mTOR Pathway in Human Glioblastoma (U87) Cells

Glioblastoma Multiforme (GBM) is a malignant primary brain tumor associated with poor survival rate. PI3K/Akt pathway is highly upregulated in gliomas due to deletion or mutation of PTEN and its activation is associated with tumor grade. mTOR is downstream from PI3K/Akt pathway and it initiates translation through its action on S6K and 4E-BP1. mTOR is an important therapeutic target in many cancers, including glioblastomas. Rapamycin and its analogues are known to inhibit mTOR pathway; however, they also show simultaneous upregulation of Akt and eIF4E survival pathways on inhibition of mTOR, rendering cells more resistant to rapamycin treatment. In this study we investigated the effect of combination treatment of rapamycin with isoflavones such as genistein and biochanin A on mTOR pathway and activation of Akt and eIF4E in human glioblastoma (U87) cells. Our results show that combination treatment of rapamycin with isoflavones, especially biochanin A at 50 μM, decreased the phosphorylation of Akt and eIF4E proteins and rendered U87 cells more sensitive to rapamycin treatment when compared to cells treated with rapamycin alone. These results suggest the importance of combining chemopreventive with chemotherapeutic agents in order to increase the efficacy of chemotherapeutic drugs.

[1]  F. Khuri,et al.  Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.

[2]  Y. Lee,et al.  Inhibitory effects of biochanin A on mouse lung tumor induced by benzo(a)pyrene. , 1991, Journal of Korean medical science.

[3]  S. Paternot,et al.  Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation. , 2009, Cancer research.

[4]  N. Sonenberg,et al.  Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy , 2012, BioDrugs.

[5]  Paul S Mischel,et al.  Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. , 2003, Cancer research.

[6]  M. Phelps,et al.  Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma , 2008, Clinical Cancer Research.

[7]  R. McLendon,et al.  Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma , 2006, Clinical Cancer Research.

[8]  A. Gingras,et al.  Regulation of translation initiation by FRAP/mTOR. , 2001, Genes & development.

[9]  P. Wen,et al.  Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas , 2006, Neurology.

[10]  H. Baker,et al.  Mechanisms of the growth inhibitory effects of the isoflavonoid biochanin A on LNCaP cells and xenografts * , 2002, The Prostate.

[11]  P. Frost,et al.  mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. , 2001, Endocrine-related cancer.

[12]  Frank McCormick,et al.  Cancer: Survival pathways meet their end , 2004, Nature.

[13]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[14]  L. V. Van Horn,et al.  Epidemiology of soy and cancer: perspectives and directions. , 1995, The Journal of nutrition.

[15]  H. Adlercreutz,et al.  Genistein, a dietary-derived inhibitor of in vitro angiogenesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Brett L Carlson,et al.  Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. , 2002, Cancer research.

[17]  M. Markman.  Cancer Medicine 6 , 2003 .

[18]  Xianglin Shi,et al.  Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. , 2003, Biochemical and biophysical research communications.

[19]  Shile Huang,et al.  Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. , 2002, Current opinion in investigational drugs.

[20]  D. A. Foster,et al.  Regulation of mTORC1 and mTORC2 Complex Assembly by Phosphatidic Acid: Competition with Rapamycin , 2008, Molecular and Cellular Biology.

[21]  S. Barnes,et al.  Biochemical Targets of the Isoflavone Genistein in Tumor Cell Lines , 1995, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[22]  M. Shibuya,et al.  Genistein, a specific inhibitor of tyrosine-specific protein kinases. , 1987, The Journal of biological chemistry.

[23]  E. Sausville,et al.  Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  A. Bhushan,et al.  Inhibition of glioma invasion of fetal brain aggregates. , 1998, In vivo.

[25]  Shile Huang,et al.  Mechanisms of resistance to rapamycins. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[26]  J. Kavanagh,et al.  Growth inhibition of prostate cell lines in vitro by phyto-oestrogens. , 1998, British journal of urology.

[27]  R. McLendon,et al.  Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. , 2005, Molecular cancer therapeutics.

[28]  M. Hidalgo,et al.  The rapamycin-sensitive signal transduction pathway as a target for cancer therapy , 2000, Oncogene.

[29]  Shilpa Puli,et al.  Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) Cells by isoflavones , 2006, Journal of Neuro-Oncology.

[30]  R. McLendon,et al.  Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma , 2009, Journal of Neuro-Oncology.

[31]  M. Gilbert,et al.  Advances in molecular therapies in patients with brain tumors. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[32]  S. Lowe,et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.

[33]  H. Ohgaki,et al.  Genetic pathways to glioblastomas , 2005, Neuropathology : official journal of the Japanese Society of Neuropathology.

[34]  E. Raymond,et al.  Lessons learned in the development of targeted therapy for malignant gliomas , 2007, Molecular Cancer Therapeutics.

[35]  H. Pehamberger,et al.  Suppression of mTOR complex 2‐dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002 , 2009, The British journal of dermatology.

[36]  Joseph Gera,et al.  mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. , 2007, Cancer research.

[37]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Avruch,et al.  Dissociation of raptor from mTOR is a mechanism of rapamycin‐induced inhibition of mTOR function , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[39]  C. James,et al.  Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. , 2005, Neoplasia.

[40]  D. Sabatini,et al.  mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.

[41]  Mechanisms of action of rapamycin in gliomas. , 2005, Neuro-oncology.

[42]  D. Louis,et al.  PTEN mutations in gliomas and glioneuronal tumors , 1998, Oncogene.

[43]  L. P. Paul,et al.  Inhibition of Epidermal Growth Factor Receptor-associated Tyrosine Kinase Blocks Glioblastoma Invasion of the Brain. , 1997, Neurosurgery.

[44]  P. Mischel,et al.  A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) , 2009, Journal of Neuro-Oncology.

[45]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[46]  M. Bjornsti,et al.  The tor pathway: a target for cancer therapy , 2004, Nature Reviews Cancer.

[47]  P. Houghton,et al.  Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. , 1994, Cancer research.

[48]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  P. Houghton,et al.  Resistance to Rapamycin: A Novel Anticancer Drug , 2004, Cancer and Metastasis Reviews.

[50]  J. Dutcher.  Mammalian Target of Rapamycin Inhibition , 2004, Clinical Cancer Research.

[51]  G. Mills,et al.  Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma , 2006, Molecular Cancer Therapeutics.

[52]  S. Horvath,et al.  Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.

[53]  R. Gemmill,et al.  Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. , 2007, Urology.

[54]  J. Olefsky,et al.  A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. , 2000, Molecular endocrinology.

[55]  M. Karsy,et al.  Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. , 2009, International journal of oncology.

[56]  P. Houghton,et al.  Studies on the mechanism of resistance to rapamycin in human cancer cells. , 1998, Molecular pharmacology.

[57]  Jie Chen,et al.  A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. , 2002, Biochemical pharmacology.

[58]  P. Pandolfi,et al.  mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. , 2005, Neoplasia.

[59]  Alona Muzikansky,et al.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  A. Bhushan,et al.  Biochanin A Modulates Cell Viability, Invasion, and Growth Promoting Signaling Pathways in HER-2-Positive Breast Cancer Cells , 2010, Journal of oncology.

[61]  D. Parolin,et al.  Regulation of glioblastoma cell invasion by PKCι and RhoB , 2008, Oncogene.

[62]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[63]  F. Kaper,et al.  Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. , 2006, Cancer research.

[64]  C ASSANASEN,et al.  GLIOBLASTOMA MULTIFORME. , 1965, Virginia medical monthly.

[65]  K. Kinzler,et al.  Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.